Samyang Biopharm Q1 2026: Revenue Growth and Net Profit Rise

Q1 2026 revenue KRW 31.17bn (+9.0% vs. prior period), operating profit KRW 1.39bn (down from KRW 2.69bn), net profit KRW 2.57bn (+14.7%), basic EPS KRW 345.
Medical device segment: revenue KRW 18.59bn (OP KRW 5.49bn); Pharmaceuticals: revenue KRW 12.45bn (OP KRW 0.72bn); New drug development: operating loss KRW 4.82bn.
Total assets KRW 353.35bn, total liabilities KRW 116.06bn, equity KRW 237.30bn. Debt-to-equity ratio 48.9%.
R&D expenditure KRW 4.71bn (15.1% of revenue), 102 patents held.
New facility loan of KRW 14bn (KDB, 2.66%, due 2033), commercial paper KRW 70bn (2.79%).
Financial costs of KRW 1.23bn including derivative valuation loss of KRW 0.34bn.
Joint liability for pre-split debts with Samyang Holdings.
No dividend declared (newly established; future strategic decisions planned).